The glutaminase inhibitor CB-839 (Telaglenastat) enhances the anti-melanoma activity of T cell mediated immunotherapies.

Immune checkpoint inhibitors and adoptive tumor-infiltrating lymphocyte (TIL) therapies have profoundly improved the survival of melanoma patients. However, a majority of patients do not respond to these agents, and many responders experience disease relapse. While numerous innovative treatments are...

Full description

Saved in:
Bibliographic Details
Published in:Mol Cancer Ther
Main Authors: Varghese, Sruthy, Pramanik, Snigdha, Williams, Leila J., Hodges, Hannah R., Hudgens, Courtney W., Fischer, Grant M., Luo, Catherine K., Knighton, Barbara, Tan, Lin, Lorenzi, Philip L., Mackinnon, Andrew L., McQuade, Jennifer L., Hailemichael, Yared, Roszik, Jason, Peng, Weiyi, Vashisht Gopal, Y. N.
Format: Artigo
Language:Inglês
Published: 2020
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC7933078/
https://ncbi.nlm.nih.gov/pubmed/33361272
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-20-0430
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items